Meiotic stage-dependent induction of chromosome aberrations in Chinese hamster primary oocytes exposed to topoisomerase II inhibitor etoposide.
To investigate the chromosomal effects of topoisomerase II (topo-II)-interactive drugs on mammalian primary oocytes, female Chinese hamsters were treated with etoposide (VP-16) at various intervals pre- and post-human chorionic gonadotropin (hCG) injections. Chromosome analysis of oocytes at metaphase II (M II) showed that treatment with VP-16 at 50h pre-hCG had no effect, but the treatments between 24h pre-hCG and 2h post-hCG often caused structural chromosome aberrations. Although treatment at 4h post-hCG had no effect, subsequent treatments at 6 and 8h post-hCG produced a significant increase in structural chromosome aberrations. No effect was found following treatment at 10h post-hCG. The incidence of aneuploidy following exposure to VP-16 was also dependent on the time of hCG injection. Taking the time course of meiotic progression in primary oocytes following hCG injection and pharmacokinetics of VP-16 into consideration, it is likely that meiotic stages from late dictyate to diakinesis are highly sensitive to VP-16, while stages at dictyate and from metaphase I (M I) to telophase I (telo I) are relatively insensitive to the drug. Moreover, the effect of VP-16 on structural chromosome aberrations and aneuploidy was dose-dependent. Chromosome analysis at M I detected a frequent occurrence of structural chromosome aberrations in treated oocytes. This suggests that structural aberrations may be caused by disruption of cleavable complexes during chromosome condensation. Detection of chromosome bridges during anaphase I/telophase I (ana I/telo I) may support the hypothesis that induction of aneuploidy by VP-16 is due to failure in decatenation of recombinant homologous chromosomes.
Tateno
H
H
Department of Biological Sciences, Asahikawa Medical College, 2-1 Midorigaoka-higashi, Asahikawa 078-8510, Japan. htateno@asahikawa-med.ac.jp
Kamiguchi
Y
Y
D000782:Aneuploidy; D000818:Animals; D002869:Chromosome Aberrations; D006224:Cricetinae; D003412:Cricetulus; D004791:Enzyme Inhibitors / Q000633:toxicity*; D005047:Etoposide / Q000633:toxicity*; D005260:Female; D008540:Meiosis / Q000187:drug effects / Q000235:genetics; D008677:Metaphase / Q000187:drug effects / Q000235:genetics; D009865:Oocytes / Q000166:cytology / Q000187:drug effects* / Q000201:enzymology; D059005:Topoisomerase II Inhibitors
D004791:Enzyme Inhibitors; D059005:Topoisomerase II Inhibitors; D005047:Etoposide